Shoulder Innovations (SI) Q3 2026 earnings review
Shoulder Innovations raises its sales plan and settles patent lawsuit
Shoulder Innovations, a maker of shoulder replacement implants, cleared a major legal hurdle while its sales growth cooled from the first half's pace. Revenue rose 38% from a year ago as surgeons used more implants and gross margin expanded to 79%. Chief executive Rob Ball raised the full-year sales outlook again, but by our math the plan has growth slowing to 31% in the fourth quarter.
| Revenue | $16.2M +38% from a year ago |
|---|---|
| Implant systems sold | 2,126 +34% from a year ago |
| Gross margin | 78.5% up 2.3 percentage points from a year ago |
| Full-year revenue outlook | Raised $1M middle of the range: 46% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the company settled its patent lawsuit with Catalyst OrthoScience and completed the first surgeries with its InSet Go socket implant a year ahead of the schedule in its prior filing. Lower legal bills also let overhead expenses fall as a share of sales. The bad news: engineering spending on the InSet Neo surgical robot doubled, keeping the operating loss stuck at $8 million.
The question now is whether slowing sales growth reflects a cautious fourth-quarter plan or real cooling as the business laps last year's surge. If new surgeon additions stay rapid, fourth-quarter sales should top the $70 million ceiling; if rival robots slow adoption, growth will settle near 30%. Fourth-quarter revenue and the year-end surgeon count will decide it.
🐂 Bull Case
Catalyst Patent Settlement Removes a Major Legal Risk
Shoulder Innovations faced a patent lawsuit and counterclaim from rival Catalyst OrthoScience over its reverse shoulder system, while management warned last quarter that selling and overhead costs would rise as a share of sales in the third quarter.
Instead, the medical device maker announced "a settlement agreement with Catalyst OrthoScience Inc. to resolve all outstanding patent litigation between the two companies". Because legal bills dropped, selling, general and administrative expenses fell to 105.8% of revenue, down from 116.9% in the second quarter and 128.2% a year ago.
This matters because the settlement removes the threat of an adverse court judgment against its main product line and lets sales growth outpace overhead costs a quarter earlier than planned.
What to watch: the legal footnote in the third-quarter filing with regulators. It will show whether the settlement requires any ongoing royalty payments or one-time cash payouts.
New Implants and Cost Cuts Lifted Gross Margin
Second-half seasonal shifts toward standard anatomic procedures usually pull down the average selling price of shoulder implants. Chief executive Rob Ball said the company "added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving".
Surgeons completed the first procedures with InSet Go, the company's next-generation socket implant. The group also launched the N-22 humeral head for patients with metal allergies and signed an "exclusive partnership with ALM Ortho to develop additively manufactured solutions for severe deformity and complex revision cases".
- Gross margin: 78.5%, up 2.3 percentage points from a year ago
- Cost of making products: 21.5% of revenue, down from 23.8% a year ago
- Average selling price: $7,616 per system, up 2.0% from a year ago
- Implant systems sold: 2,126 units, up 34.2% from a year ago
New premium products and supplier cost reductions protected profitability, so gross margin rose 0.2 percentage points from the second quarter even as the average selling price dipped 0.8%.
What to watch: fourth-quarter gross margin and average selling price. Holding gross margin near 78.5% would show that new implant launches can offset seasonal price dips.
🐻 Bear Case
Revenue Growth Is Slowing Toward 31% in Q4
Shoulder Innovations has raised its full-year sales outlook every quarter this year, and Ball promoted Jon Osborne to Chief Commercial Officer to lead territory expansion. Even so, each outlook raise has been smaller than the one before it.
Third-quarter revenue rose 37.7% from a year ago to $16.2 million, slowing from 56.0% growth in the second quarter and 64.9% in the first. Revenue fell 5.7% from the second quarter as implant volume dropped 5.0%.
Management lifted the full-year outlook by $1 million to $68–70 million. By our math, that leaves $17.9–19.9 million of revenue for the fourth quarter, or 31.3% growth at the middle of the range against a tough 65.2% comparison a year ago. Because the third quarter already slowed below 40%, the company's rapid expansion rate is cooling as its revenue base gets larger.
What to watch: the year-end count of core and contender surgeons — doctors who perform at least three procedures a quarter — in the fourth-quarter report. A sharp rise from last year's 134 surgeons would show that underlying hospital adoption remains fast.
Robotics Spending Kept the Operating Loss at $7.6M
The press release highlights that net loss narrowed to $7.0 million from $8.7 million a year ago, and that loss before interest, taxes, depreciation and stock compensation shrank by $2.0 million. Ball noted the team is building momentum for 2027, "including the planned FDA submission of InSet Neo, our shoulder-specific robotic platform".
To prepare that submission, the implant maker more than doubled research and development spending to $3.2 million, or 19.5% of revenue compared with 13.0% a year ago. That extra engineering bill wiped out the gross profit gains, leaving the operating loss unchanged at $7.6 million.
The headline net loss only looked smaller because last year's third quarter included a $2.2 million accounting charge on convertible notes. Excluding that one-time charge by our math, last year's net loss was $6.5 million, so the underlying bottom-line loss actually widened by $0.5 million.
What to watch: research and development spending in the fourth quarter. If engineering costs stay above $3 million a quarter, operating losses will not shrink until revenue grows much larger.
Risks this quarter didn't answer
Three standing concerns from prior filings received no new numbers in the third-quarter earnings release.
- Related-party software payments: the release does not show third-quarter development and consulting fees paid to Genesis entities affiliated with the chief executive; the quarterly filing's related-party footnote will provide the figure.
- Rival shoulder robot: an incumbent competitor has already launched a shoulder robotic system ahead of InSet Neo's planned 2027 regulatory filing; surgeon retention numbers at year-end will test whether rivals are slowing adoption.
- Pre-IPO share registration: the release does not update the status of registering insider and early-investor shares after the one-year anniversary of the August 2025 listing; regulatory filings will show any share sales.
💲 Other KPIs
Total cash and marketable securities fell by $6.7 million from $99.0 million at the end of the second quarter, and is down from $124.3 million at the end of 2025. With long-term debt steady at $14.8 million and quarterly cash burn under $7 million, the balance sheet still covers more than three years of operations at the current pace.
Inventories rose 6.4% from the second quarter to $24.4 million, up 12.9% since the end of 2025 to stock new implant lines like InSet Go and N-22. Trade accounts receivable — money hospitals owe for implants already used — stood at $9.3 million, up 12.3% since year-end while nine-month sales rose 52.2%, showing fast cash collection.
Basic and diluted share count rose 53.2% from a year ago because the August 2025 initial public offering fell partway through last year's third quarter. Compared with the second quarter of 2026, share count edged up just 0.5% from employee stock option exercises.
🔮 Guidance
Raised. Management lifted the full-year sales plan by $1 million, calling for 44% to 48% growth over 2025. By our math, that leaves $18.9 million at the middle of the range for the fourth quarter, or 31.3% growth from a year ago compared with 37.7% in the third quarter. It is the third raise this year, and each is smaller than the last: +$3.0M, +$1.5M, +$1.0M.
❓ Key Questions
What are the financial terms of the Catalyst patent settlement?
The company settled all patent litigation with Catalyst OrthoScience and noted lower legal expenses in the quarter. Investors need to know whether the deal includes a one-time payment or ongoing royalties on reverse shoulder implants.
How much went to CEO-affiliated Genesis entities in Q3?
In the first half of 2026, software development and consulting payments to related-party Genesis entities nearly doubled to $8.0 million. The press release does not disclose third-quarter related-party spending.
How many core and contender surgeons were active in Q3?
Chief executive Rob Ball said the team added new surgeons ahead of plan, but the company only prints its core and contender surgeon count once a year. Disclosing the count quarterly would clarify whether slowing unit growth is purely seasonal.
Why does the Q4 outlook point to 31% growth?
The fourth quarter is usually the busiest season for shoulder procedures, and InSet Go just completed its first cases. Management has not quantified how much of the fourth-quarter growth step-down is tough comparisons versus conservative planning.